Mastocytosis: Clinical Trials

14 trials for Mastocytosis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

8 completed, 4 unknown, 1 recruiting, 1 terminated. 14 Phase 3, 5 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 314Completed 8, Unknown 4, Recruiting 1, Terminated 1
Phase 25Completed 2, Unknown 2, Recruiting 1

Follow Mastocytosis: new trials by email Literature Review of Mastocytosis trials Research Report on Mastocytosis

Trials (filtered) newest first · largest first

All 14 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis
Elenestinib, Placebo - Indolent Systemic Mastocytosis, Smoldering Systemic Mastocytosis
Phase 2 / Phase 3RecruitingBlueprint Medicines Corporation5342021-11-302026-10-07
Hydroxychloroquine in Isolated Cutaneous Mastocytosis Patients or Indolent Systemic Mastocytosis With Associated Skin Involvement Patients
Hydroxychloroquine - Mastocytosis
Phase 2 / Phase 3UnknownUniversity Hospital, Toulouse302021-10-012021-10-20
Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis Unresponsive to Optimal Symptomatic Treatment
Masitinib, Placebo, Best Supportive Care - Indolent Systemic Mastocytosis
Phase 3UnknownAB Science1402020-07-012023-05-06
Interest of Denosumab Treatment in Osteoporosis Associated to Systemic Mastocytosis
Denosumab, Placebo - Osteoporosis, Systemic Mastocytosis
Phase 3CompletedAssistance Publique - Hôpitaux de Paris242018-03-052026-03-31
Cladribine Plus Pegylated Interpheron Alfa-2a in Systemic Mastocytosis
Cladribine and pegylated interpheron alpha-2a - Systemic Mastocytosis
Phase 2 / Phase 3UnknownHospital Virgen de la Salud102012-05-012016-08-29
The Effect of Xolair ® (Omalizumab) in Mastocytosis Patients
injections - Mastocytosis
Phase 2 / Phase 3CompletedUniversity of Zurich172011-09-012016-01-18
Study on Mastocytosis for Rupatadine Treatment
Rupatadin - Mastocytosis
Phase 2 / Phase 3CompletedMarcus Maurer302010-09-012016-11-03
Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer
cyproheptadine hydrochloride, placebo - Cancer
Phase 3TerminatedUniversity of South Florida222010-06-012015-07-02
Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain
ketamine hydrochloride, pharmacogenomic studies, questionnaire administration - Cancer
Phase 3UnknownUniversity of Glasgow2142009-04-012011-05-13
Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis
Masitinib, Placebo, Best Supportive Care - Indolent Systemic Mastocytosis
Phase 3CompletedAB Science1352008-12-012019-12-03
American Ginseng in Treating Patients With Fatigue Caused by Cancer
American ginseng, placebo - Chronic Myeloproliferative Disorders, Fatigue
Phase 3CompletedAlliance for Clinical Trials in Oncology3642008-10-012017-02-09
Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial
educational intervention - Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders
Phase 3CompletedCase Comprehensive Cancer Center5832008-04-012020-07-27
Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer
darbepoetin alfa, ferrous sulfate, sodium ferric gluconate complex in sucrose - Anemia, Leukemia
Phase 3CompletedMayo Clinic5022006-01-012011-05-17
Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain
educational intervention, Titrated pain management, questionnaire administration - Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders
Phase 3CompletedVanderbilt-Ingram Cancer Center982005-05-012012-09-06

Narrower conditions

Lymphoma, Large-Cell, Anaplastic (6)  ·  Burkitt Lymphoma (5)  ·  Hodgkin Disease (5)  ·  Immunoblastic Lymphadenopathy (5)  ·  Immunoglobulin Light-chain Amyloidosis (5)  ·  Leukemia, Biphenotypic, Acute (5)  ·  Leukemia, Hairy Cell (5)  ·  Leukemia, Large Granular Lymphocytic (5)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (5)  ·  Leukemia, Mast-Cell (5)  ·  Leukemia, Prolymphocytic (5)  ·  Lymphoma, B-Cell, Marginal Zone (5)  ·  Lymphoma, Extranodal NK-T-Cell (5)  ·  Lymphoma, Follicular (5)

Broader conditions

Immune System Diseases (14)  ·  Neoplasms by Histologic Type (14)  ·  Mast Cell Activation Disorders (13)  ·  Neoplasms (12)  ·  Neoplasms, Connective Tissue (9)  ·  Neoplasms, Connective and Soft Tissue (9)  ·  Metabolic Diseases (8)  ·  Nutritional and Metabolic Diseases (8)  ·  Pathological Conditions, Signs and Symptoms (8)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (7)  ·  Hemic and Lymphatic Diseases (6)  ·  Immunoproliferative Disorders (6)  ·  Lymphatic Diseases (6)  ·  Lymphoma, T-Cell (6)

Interventions

Early Intervention, Educational (2)  ·  masitinib (2)  ·  Asian ginseng (1)  ·  Cladribine (1)  ·  Cyproheptadine (1)  ·  Darbepoetin alfa (1)  ·  Denosumab (1)  ·  Hydroxychloroquine (1)  ·  Injections (1)  ·  Ketamine (1)  ·  Pharmacogenomic Testing (1)  ·  Sucrose (1)  ·  ferric gluconate (1)  ·  ferrous sulfate (1)

Sponsors

AB Science (2)  ·  Alliance for Clinical Trials in Oncology (1)  ·  Assistance Publique - Hôpitaux de Paris (1)  ·  Blueprint Medicines Corporation (1)  ·  Case Comprehensive Cancer Center (1)  ·  Hospital Virgen de la Salud (1)  ·  Marcus Maurer (1)  ·  Mayo Clinic (1)  ·  University Hospital, Toulouse (1)  ·  University of Glasgow (1)  ·  University of South Florida (1)  ·  University of Zurich (1)  ·  Vanderbilt-Ingram Cancer Center (1)

Countries

United States (7)  ·  France (5)  ·  Germany (3)  ·  United Kingdom (3)  ·  Netherlands (2)  ·  Poland (2)  ·  Romania (2)  ·  Spain (2)  ·  Switzerland (2)  ·  Argentina (1)  ·  Australia (1)  ·  Austria (1)  ·  Belgium (1)  ·  Brazil (1)  ·  Chile (1)

Top investigators

Barry J.A. Laird, MD (1)  ·  Charles L. Loprinzi, MD (1)  ·  Cristina Bulai Livideanu, MD, MSc (1)  ·  Debra Barton, RN, PhD, AOCN, FAAN (1)  ·  Jeffrey P. Krischer, PhD (1)  ·  Luis Escribano, MD, PhD (1)  ·  Maella Severino-Freire, MD (1)  ·  Marcus Maurer, MD (1)  ·  Marie T. Fallon (1)  ·  Nancy Wells, DNSc, RN (1)  ·  Neal J. Meropol, MD (1)  ·  Olivier Hermine, MD (1)  ·  Olivier Lortholary, MD, PhD (1)

Results publications

PMID 26700120, PMID 26700123, PMID 28069279, PMID 36048877

NIH funding

2016 (2), P30CA015083 (1), P30CA068485 (1), R01CA127655 (1), U10CA081920 (1)